Brian Camilleri
A5042352992- Renal Transplantation Outcomes and Treatments
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Organ Transplantation Techniques and Outcomes
- Renal and Vascular Pathologies
- Organ Donation and Transplantation
- Vasculitis and related conditions
- SARS-CoV-2 and COVID-19 Research
- Neurological and metabolic disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Dialysis and Renal Disease Management
- Parathyroid Disorders and Treatments
- Otitis Media and Relapsing Polychondritis
- Neurological Complications and Syndromes
- Diabetes Treatment and Management
- Stroke Rehabilitation and Recovery
- Hip disorders and treatments
- Biomedical Research and Pathophysiology
- SARS-CoV-2 detection and testing
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hypertrophic osteoarthropathy and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Spinal Fractures and Fixation Techniques
- Gout, Hyperuricemia, Uric Acid
Cardiff University
2024
The Royal Free Hospital
2024
Roland Hill (United Kingdom)
2024
University College London
2024
Ipswich Hospital
2004-2023
University of Oxford
2023
Florey Institute of Neuroscience and Mental Health
2016-2020
The University of Melbourne
2020
Austin Health
2020
Peninsula Health
2020
Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) a prospective observational cohort patients enrolled into the induction phase RITAZAREM trial.
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially patients history relapse. Relapses associated increased exposure to immunosuppressive medications, the accrual damage and morbidity mortality. The RITAZAREM trial compared efficacy repeat-dose daily oral azathioprine for prevention relapsing AAV whom was reinduced rituximab. Methods an international randomised controlled, open-label,...
BackgroundIndividuals with rare kidney diseases account for 5–10% of people chronic disease, but constitute more than 25% patients receiving replacement therapy. The National Registry Rare Kidney Diseases (RaDaR) gathers longitudinal data from these conditions, which we used to study disease progression and outcomes death failure.MethodsPeople aged 0–96 years living 28 types were recruited 108 UK renal care facilities. primary cumulative incidence mortality failure in individuals diseases,...
The National Registry of Rare Kidney Diseases (RaDaR) collects data from people living with rare kidney diseases across the UK, and is world's largest, disease registry. We present clinical demographics renal function 25,880 prevalent patients sought evidence bias in recruitment to RaDaR.
Urinary tract infections (UTI) are common in adults and known to cause deterioration renal function patients with chronic impairment, solitary kidneys transplants. Acute non-obstructive pyelonephritis is rarely considered the differential diagnosis of acute failure (ARF), especially little or no evidence previous kidney disease. Diagnosis particularly difficult if infection asymptomatic. Chronic alcohol abuse increases risk ARF unobstructed [1] a rare papillary necrosis [2,3]. We present an...
Kidney transplantation is the treatment of choice for patients with end-stage renal failure. Living kidney donation has increased over past few years and now accounts 34% total transplant programme in UK. Reasons increase living include shortage deceased donor organs possibility to perform pre-emptive antibody-incompatible transplantation. In addition, some prefer as this option associated better patient graft survival. However, although considered safe low-risk individuals, it important...